Lezing 'Targeting GARP on Tregs: a novel approach for the immunotherapy of cancer'

Voor wie
Studenten, Medewerkers, Alumni, Bedrijven
02-03-2018 van 11:30 tot 12:45
UGent-VIB-onderzoeksgebouw, Technologiepark 927, 9052 Zwijnaarde
Door wie
VIB-UGent Center for Inflammation Research (GE01/WE14/WE10)
Voeg toe aan mijn agenda

Sophie Lucas (de Duve Institute, UCL) will show us how antibodies against the GARP membrane protein block regulatory T cell function in cancer

Regulatory T lymphocytes (Tregs) are essential to prevent auto-immunity, but excessive Treg function contributes to cancer progression by inhibiting anti-tumor immune responses. Tregs exert contact-dependent inhibition of immune cells through the production of active TGF-beta1. On the Treg cell surface, TGF-beta1 is in an inactive form bound to membrane protein GARP and then activated by an unknown mechanism. We demonstrate that GARP is involved in this activation mechanism. We generated anti-GARP monoclonal antibodies that block the production of active TGF-beta1 by Tregs. Altogether, our data show that anti-GARP antibodies may serve as therapeutic tools to boost immune responses to infection or cancer, via a mechanism of action distinct from that of currently available immunomodulatory antibodies. Used alone or in combination with other therapeutic reagents, blocking anti-GARP antibodies may improve the efficiency of cancer immunotherapy.